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Objectives: The objective of the project is to evaluate the impact of health care 
resources and the related health care costs in relation to outcomes occurred in 10 
years on the cohort of 2002 and intervention on secondary prevention cohort 2010 
with a follow-up to 3 years. MethOds: In 2002, Local HealthCare Unit (ASLn°1) 
of Milan identified a cohort of 33,977 patients with RCV (Cardiovascular risk). 
Data analysis was done trough a retrospective claims data study from ASLn°1 
of Milan; Physicians who participated were 494. Information has been collected 
for inclusion in the study regarding some risk factors and treatment. At the end 
of 2010, all recruited patients were started on a program of secondary preven-
tion, by reducing the effects of smoking and BMI after ad hoc training events 
for physicians. Results: 12,000 subjects were recruited and followed for 3 years 
with reduction of spending on the NHS system and reduced incidence of events. 
A resources utilization analysis has been developed using profiles of treatments 
and dividing the population into groups with homogeneous treatment (smoking 
and BMI control vs. standard care), verifying the occurrence of greater outcomes 
and related health care costs. Data are analyzed with the definition of major car-
diovascular events, all-cause mortality and cause-specific, occurrence of diabetes 
and other chronic greater diseases, verifying the occurrence of greater outcomes 
and related health care costs. cOnclusiOns: Administrative databases offer 
low-cost information (since they are already available) regarding more or less all 
services provided in a health care environment. These sources and their integra-
tion are a powerful tool supporting conventional methods used in epidemiological 
studies and as tools for plan Health care policy.
CardiovasCular disorders – Patient-reported outcomes & Patient Prefer-
ence studies
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Objectives: To examine the relationship between medication compliance, cardio-
vascular risk and gender in hypertensive patients visiting primary health care cent-
ers. MethOds: A prospective 1-year study was conducted in rural communes in 
Vietnam on hypertension management in a population from 35 to 64 years. Data on 
age, gender, blood pressure and blood test were collected at baseline. Cardiovascular 
risk was based on the Cardiovascular Risk Prediction Model for populations in 
Asia. Medication compliance was calculated as the number of days taking the drug 
divided by the number of days since the first day of the prescription. A threshold of 
80% was applied to differentiate between compliance or non-compliance. Taking 
medication was based on patients’ self-report during each monthly visit. Results: 
Of total 338 patients met the selection criteria for medication compliance study, 
46% was female. Mean age was 53.5 (+/- 6.9) and 77.2 % of patients was < 10% of 
CVD risk in 8 years. In primary health care settings, medication compliance was 
49%. No significant difference in medication compliance in both CVD risk groups 
(< 10% vs. > 10% risk) was found, also not after controlling for age and gender 
(adjusted OR was 1.27; 95 % CI: 0.7 – 2.2; p value 0.39). The odds of medication com-
pliance in females was however 0.6 times higher than in males (95% CI: 0.38 to 0.95, 
p value 0.028). Each 1 year increase, results in patients being 1.04 times more likely 
to be compliant (95% CI: 1.009 to 1.076, p value 0.01). cOnclusiOns: Medication 
compliance rate was low among hypertensive patients in Vietnam. CVD risk at the 
baseline did not significantly differentiate complaint from non-compliant patients. 
Yet, a major difference in compliance was found for gender. Rather than risk profile, 
gender should be considered for guiding the choice on who to target for improving 
medication compliance for hypertensive patients.
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Objectives: To explore the associations of selected health behaviors with medica-
tion adherence in elderly patients aged 65+ years with hypertension, diabetes, or 
hyperlipidemia. MethOds: The Korean National Health Insurance data between 
January 2010 and June 2011 were used. The study included 662,170 hypertensive, 
179,285 diabetic, and 244,702 hyperlipidemic patients. Poor medication adher-
ence was defined as < 80% medication possession ratio from January to June 2011. 
Health behavior data were from year 2010. Multivariate logistic regression was 
used. Results: Patients with a waist circumference < 85 (for women) or 90 (for 
men) centimeters were more likely to adhere to their medications. Current smok-
ers and moderate or heavy drinkers showed poor medication adherence than their 
counterparts. Mild physical activity was associated with better medication adher-
ence. cOnclusiOns: Public efforts need to focus on improving comprehensive 
control of both health behaviors and medication adherence.
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Objectives: More than half of people who have experienced a myocardial infarc-
tion (MI) are not adherent to their medication regimen, which leads to poorer health 
outcomes. We used a stated-preference (SP) study to examine factors that could 
influence patient compliance to prophylactic cardiovascular treatments, and discuss 
practical issues in using SP methods to explain medication adherence. MethOds: 
Preference data for treatments that lower the risk of cardiovascular events were 
collected from 464 respondents in the United States with self-reported history of MI 
using a discrete-choice experiment (DCE). All respondents answered 11 judgment 
unknown risk cohort (n= 2,497; 86 days). The annual indirect cost related to work 
productivity loss was estimated at 209,704 SEK for treated hyperlipidemia patients 
with CV event history. Corresponding data for CV RE patients and patients at low/
unknown risk were 168,517 SEK and 108,429 SEK, respectively. The higher CV risk 
levels were associated with greater productivity losses. Indirect costs varied within 
cohorts depending on past diagnoses of the patients. In patients with CV event his-
tory, a previous diagnosis of myocardial infarction was associated with the lowest 
annual indirect costs (189,114 SEK) while a past diagnosis of ischemic stroke was 
associated with the highest indirect costs (281,985 SEK). Within the CV RE cohort, a 
previous diagnosis of abdominal aortic aneurysm and transient ischemic attack was 
associated with the highest (264,441 SEK) and lowest annual indirect costs (156,254 
SEK), respectively. cOnclusiOns: The high level of productivity losses illustrates 
the high indirect cost burden in patients treated for hyperlipidemia. The type of 
past CV event affected the level of indirect costs.
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Objectives: To estimate annual incremental health care costs of new cardiovascu-
lar (CV) events (myocardial infarction, unstable angina, revascularization, ischemic 
stroke, transient ischemic attack or heart failure) in patients with hyperlipidemia 
or prior CV events. MethOds: A retrospective population-based cohort study was 
conducted using Swedish electronic medical records and national registers. Patients 
were included in the study based on a prescription of lipid-lowering treatment 
between January 1, 2006 and December 31, 2006 or history of CV events (prior to 
2006) and followed until December 31, 2012 for identification of new CV events and 
estimation of cost. Patients were stratified into three cohorts based on CV risk level. 
Propensity score matching was applied to compare patients with new events to 
patients without new events and to estimate incremental costs. Results: A new 
CV event resulted in increased costs during all follow-up years. Inpatient hospital 
stays were the main driver of the increase. The majority of the costs occurred in 
the first year following event when patients with CV event history (n= 6,881) had 
an incremental cost of 74,758 SEK. This was similar to that of CV risk-equivalent 
patients (n= 3,226; 75,415 SEK) and patients at low/unknown CV risk (n= 2,497; 72,635 
SEK). Ischemic stroke resulted in the highest first year cost in all cohorts (88,739; 
85,516; and 87,668 SEK) and transient ischemic attack the lowest (34,098; 36,042; 
and 29,052 SEK). Incremental costs during subsequent years remained elevated for 
all cohorts, with the CV event history cohort having the highest costs. Second year 
incremental costs varied between 10,689 and 15,082 SEK and third year costs varied 
between 8,828 and 11,558 SEK across cohorts. cOnclusiOns: The direct costs of 
new CV events were substantial and varied considerably by type of event. Costs were 
increased during all follow-up years, regardless of CV risk level.
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Objectives: As part of a non-interventional study, hospitalizations due to the 
following diagnoses of cardiovascular disease (CVD) were documented: atrial fibril-
lation (AF), stroke or TIA (SoT), acute coronary syndrome (ACS), arterial embo-
lism (AE), decompensated heart failure (DHF), syncope (S), ventricular arrhythmia 
(VA), and cardiac arrest (CA). The objective of this cost analysis was to quantify 
inpatient treatment costs for each diagnosis in Germany from the perspective of 
the statutory health insurance. MethOds: The analysis was conducted for 2012 
using the latest available “G-DRG V2013 Browser 2012 § 21 KHEntgG”. Invoiced 
diagnosis-related groups (DRGs) including the ICD10-codes corresponding to the 
considered diagnoses were collected. For available DRGs, the number of cases with 
normal length of stay and the corresponding cost weights (CWs) were documented. 
Then, the proportion of an individual DRG within a diagnosis (≥ 1 ICD10-code) 
was calculated (number of cases for individual DRG / sum of all cases for every 
DRG within a diagnosis = “DRG weight factor”). Next, the CWs of an individual 
DRG were multiplied by the “DRG weight factor” to reflect the prevalence of a DRG 
within an ICD10-code (“weighted CWs”). Finally, the “weighted CWs” were added 
up to obtain an average CW for a diagnosis, which is based on all DRGs and CWs 
coded for this single diagnosis. This sum of CWs was multiplied by the state-wide 
base rate of 2,991.53€ . Results: The following inpatient treatment costs for the 
respective diagnoses were derived: 2,800€ (AF); 5,000€ (SoT); 5,200€ (ACS); 6,200€ 
(AE); 3,800€ (DHF); 1,900€ (S); 8,200€ (VA); 15,900€ (CA) (rounded). cOnclusiOns: 
Inpatient treatment costs for the considered CVD diagnoses vary from 1,900€ to 
15,900€ . Generally, hospitalizations due to CVD have a remarkable impact on the 
budget of German sick funds. The results of this cost study can be used for further 
health economic analyses in CVD.
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